Quick Answer
Spero Therapeutics, Inc. reported Total Revenue of $66.80 million for fiscal year 2025.
Spero Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $66.80M | +39.2% |
| 2024 | $47.98M | -53.8% |
| 2023 | $103.78M | +94.0% |
| 2022 | $53.51M | +193.1% |
| 2021 | $18.26M | +95.7% |
| 2020 | $9.33M | -48.6% |
| 2019 | $18.15M | +357.6% |
| 2018 | $3.97M | +100.4% |
| 2017 | $1.98M | +490.7% |
| 2016 | $335.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.44M | -59.6% | -61.6% |
| June 30, 2025 | $14.19M | +39.1% | +141.6% |
| March 31, 2025 | $5.87M | -36.6% | -56.4% |
| September 30, 2024 | $13.47M | -47.1% | +32.1% |
| June 30, 2024 | $10.20M | +275.4% | +10.0% |
| March 31, 2024 | $9.27M | +347.9% | -63.6% |
| September 30, 2023 | $25.47M | +1169.8% | +837.9% |
| June 30, 2023 | $2.72M | +36.3% | +31.3% |
- Spero Therapeutics, Inc. showed an increase of +39.2% in Total Revenue compared to the prior fiscal year.
- Over the 2016–2025 period, Spero Therapeutics, Inc.’s total revenue has grown by 19840.9% (from $335.0 thousand to $66.80 million).
- The most recent figure is from Spero Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: